

Q2 20-21 Performance In Delivering

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
46379	19/YH/0072	257713	A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 CO-ADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO <18 YEARS OF AGE WITH MODERATE TO SEVERELY ACTIVE CROHN'S DISEASE	Range Agreed	0	0	Date Agreed	22/11/2019	0	22/11/2019	0	Recruitment Finished	No eligible patients
46380	18/LO/0381	240085	A Phase II/III Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Safety and Efficacy of BI 655130 Induction Therapy in patients with moderate-to-severely active ulcerative colitis who have failed previous biologics therapy	Number Agreed	2	2	Date Agreed	31/05/2020	2	04/02/2020	2	Recruitment Finished	
46381	19/LO/0397	243173	A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease	Number Agreed	1	1	Date Agreed	01/05/2021	0	06/02/2020	0	Withdrawn By Host	Barnsley have withdrawn from the study at this time due to concerns regarding the IMP preparation
46382	17/NE/0351	235420	A PERFORMANCE EVALUATION STUDY OF ARQUER'S MCM5 ELISA TEST TO AID IN THE DIAGNOSIS OF PROSTATE CANCER	Number Agreed	13	13	Date Agreed	31/03/2020	13	31/03/2020	13	Recruitment Finished	
46383	18/NE/0312	245315	A Phase 3 Randomized, Double-blind, Multi-Centre, Long-term Extension Study Investigating The Efficacy And Safety Of PF-04965842, With Or Without Topical Medications, Administered To Subjects 12 years And Over With Moderate-To-Severe Atopic Dermatitis	Number Agreed	1	1	Date Agreed	07/07/2020	1	22/11/2019	1	Recruitment Finished	early finish
46406	17/EE/0401	224915	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment	Number Agreed	3	3	Date Agreed	29/07/2020	0	24/07/2020	0	Recruitment Finished	early finish - closed by sponsor
46407	17/EE/0402	224923	A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991.1	Number Agreed	0	0	Date Agreed	30/09/2020	0	24/07/2020	0	Recruitment Finished	feeder study closed with) patients, no patients to roll over therefore closed